This content is machine translated Multiple sclerosis Personalized medicine at the cutting edge Intensive research in the field of multiple sclerosis (MS) has led to the availability of different treatment options – depending on the form of the disease and its severity. This…
View Post 3 min This content is machine translated CLL11 study Combination of chlorambucil and CD20 antibody the new standard as early as 2014? In an interview with InFo ONCOLOGY & HEMATOLOGY, Michael Gregor, MD, of Lucerne Cantonal Hospital, talks about the CLL11 trial. It addresses the study population, the most relevant results, and…
View Post 4 min This content is machine translated HER2-positive breast cancer and lymphoma New applications and antibodies The antibody-drug conjugate trastuzumab emtansine, T-DM1 (Kadcyla®), is composed of the antibody trastuzumab and the chemotherapeutic agent DM1 and is currently being investigated for the treatment of HER2-positive cancers. It…
View Post 4 min This content is machine translated Chronic lymphocytic leukemia New therapies urgently needed At the ESMO Congress in Amsterdam, speakers from various countries discussed the latest results and therapy recommendations in the field of chronic lymphocytic leukemia. Overall, chemoimmunotherapy with fludarabine, cyclophosphamide (FC),…
